Drugs / HER2-targeted CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07066982 | May 2025 → Dec 2027 expected | Ewing sarcoma, Kaposi's sarcoma, bone sarcoma, malignant germ cell tumor +1 | Essen Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2-targeted CAR T cells | “first an infusion of CD146-targeted CAR T cells, then an infusion of HER2-targeted CAR T cells.” NCT07066982 ↗ |
| Modality | Cell therapy | “CD146/HER2 Chimeric Antigen Receptor T (CAR T) cells” NCT07066982 ↗ |
| Route | Intravenous | “patients will receive CD146 HER-2 CAR T cells intravenously (IV)” NCT07066982 ↗ |